June 23rd 2025
A total of 13 drugs were granted recommendation for market authorization at EMA’s CHMP June 2025 meeting.
Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.
June 19th 2025
NIBRT, Firefinch, and eg technology will join the center, adding to its collective of healthcare innovators.
The new facility offers cleanroom packaging and high-sensitivity analytical testing.
June 18th 2025
The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for shortened drug approval review time.
Securing the Single-Use Supply Chain
Dual sourcing is one of many possible solutions to securing the supply chain.
Part VII GMPs for Small Molecule Drugs in Early Development Workshop Summary
The authors explore and define common industry approaches and practices when applying GMPs in early development.
A Next Generation of Quality Management
The author proposes a quality management system that uses the power of executive management to promote a positive quality culture.
Good Distribution Practices: Who is Responsible?
Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses the requirements for good distribution practices.
Breakthrough Successes Create Manufacturing Challenges
Sponsor response to FDA's breakthrough program has exceeded FDA expectations, but puts pressure on manufacturers to address formulation, stability and quality production issues very early in development.
Moving from Corrective to Preventive Actions
Enterprise quality management systems can help shift the quality emphasis from corrective to preventive actions.
Generic Drugs Face New Regulatory Future
Manufacturers face regulatory overhaul, while brand-generic debates escalate over biosimilars and labeling changes.
Aurobindo Pharma USA Recalls One Lot of Gabapentin Capsules
Aurobindo Pharma USA issued a voluntary nationwide recall of Northstar Label Gabapentin Capsules, USP 300 mg, due to complaints of empty capsules.
Baxter Recalls One Lot of Highly Concentrated Potassium Chloride Injection
The Baxter recall in the US of one lot of highly concentrated potassium chloride is due to a mislabeled overpouch.
FDA to Increase its Ties to China
Margaret Hamburg, FDA Commissioner, visited China recently to oversee efforts to strengthen inspection and regulatory reviews and to attend the Ninth International Summit of Heads of Medicines Regulatory Agencies Meeting
Manufacturing Issues Crucial to Combating Ebola
The United States government is ramping up support for formulation, production, and packaging of Ebola treatments.
FDA Requests Comments on Generic Drug Submission Criteria
FDA opens public docket on proposed criteria for “first generic” ANDAs.
EMA Revises Policy on Conflict of Interests
Revised EMA policy reflects more balanced approach and experts are to submit updated declarations of interests by end of January 2015.
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
USP and ChP jointly host two-day meeting to strengthen cooperation.
GPhA Issues Statement on Generic Drug Costs
Ralph G. Neas, president and CEO of the Generic Pharmaceutical Association, requests that Congress get involved in the support of a more competitive drug market.
FDA Issues Draft Guidance on Rare Pediatric Diseases
FDA issues draft guidance on rare pediatric disease priority review vouchers in accordance with FDASIA.
AQbD Adds Rigor to Method Development
Analytical procedures and method validation should be developed with a structured and rigorous approach.
FDA Issues Warning Letter to Cadila Pharmaceuticals for CGMP Deviations
The agency cites deviations from CGMPs for the manufacture of APIs at the company?s Gujarat, India plant.
USP Releases Compounding Compendium
USP releases compendium of quality standards for compounded medicines.
FDA Fast Tracks Threshold Pharmaceuticals' Anticancer Drug
Threshold Pharmaceuticals' anticancer drug TH-302 receives FDA Fast Track designation.
EMA Responds to Questions about Confidential Information
The European Medicines Agency responds to the European Ombudsman?s letter regarding redacted documents.
FDA Specifies DUNS for Drug Facility Registration
FDA releases guidance specifying its preferred unique facility identifier system.
Hikma Pharmaceuticals Warned About CGMP Violations at Portuguese Facility
An FDA warning letter to Hikma Pharmaceuticals cites violations of CGMP at its plant in Portugal that manufactures finished drugs.
New Era for Generic Drugs
Tackling Drug Shortages
Resolving the problem will require more communication between the industry and regulatory bodies.
Parenterals, Particulates, and Quality by Design
The parenteral manufacturing industry is taking action to address particulate contamination issues.
GMPs for Small-Molecule Drugs in Early Development: Workshop Summary-Part VI
Germany Post AMNOG: Insights for BioPharma
The authors take a look at some of the recent developments in the German pharmaceutical market.
A Robust CAPA System for a Global Supply Chain
Mission: Close Gaps in the Supply Chain
Supply chain security and quality group Rx-360 driven by patient safety.